대한뉴팜

Daehan Nupharm announced on the 26th that it is participating in “Cosmoprof CBE Asean Bangkok 2025”, which is currently being held in Bangkok, Thailand. The exhibition, hosted in Thailand’s rapidly growing beauty and medical aesthetics market (estimated at USD 6.6 billion), has been drawing increasing global attention since moving its venue to central Bangkok in 2023. At this year’s event, Daehan Nupharm is showcasing a diverse portfolio, including Luthione Injection, anesthetic creams, PLA fillers, facial mask packs, and diagnostic kits. Thailand has shown strong and growing demand for K-beauty and Korean-made medical products, with imports rising significantly over the past three years. Korea currently holds the No. 1 market share in cosmetics imported into Thailand and ranks 10th in medical device imports, reflecting the country’s robust growth driven by active market expansion efforts from Korean companies. Daehan Nupharm has been actively expanding its global presence, having completed overseas registration for 75 products to date, with 11 additional products registered in 2024 alone. The company has established a broad export network spanning Southeast Asia, Central Asia, the Middle East, South America, and New Zealand. Pharmaceutical product registration requires CTD (Common Technical Document) submissions, which include extensive data on raw materials, manufacturing processes, and toxicology studies. Because this process — including site inspections — can take several years depending on the country, a strategic approach backed by specialized expertise is essential. Daehan Nupharm is pursuing a long-term export growth strategy ahead of the full operation of its new Hyangnam GMP facility in 2027. Participating in global exhibitions is a key part of this plan. While the company’s appearance at last year’s Cosmoprof Hong Kong focused on identifying demand for its new products such as PLA fillers and anesthetic creams, this year’s Bangkok exhibition aims to promote finished products, conduct sample testing with potential buyers, and generate export revenue starting in the second half of 2025.

Amid a severe nationwide influenza outbreak in Korea, Daehan Nupharm has reported a sharp increase in demand for its “Enpiflu Premix Injection,” a one-shot IV treatment for influenza. The number of flu patients visiting medical facilities has skyrocketed to more than ten times the usual levels, with some pharmacies already experiencing shortages of flu treatments and cold medicines. According to the Korea Disease Control and Prevention Agency (KDCA), the number of suspected influenza outpatients during the last week of December 2024 (December 22) reached 73.9 per 1,000, up from 7.3 per 1,000 in early December—a tenfold increase and the highest figure since the major flu outbreak in 2016. Influenza typically presents with sudden high fever (over 38 °C), headache, muscle pain, fatigue, and respiratory symptoms such as cough, sore throat, and sputum production. If left untreated in the early stages, it can lead to complications including pneumonia, bronchitis, and worsening of chronic conditions. Enpiflu Premix Injection is a peramivir hydrate-based formulation that treats influenza with a single intravenous dose, unlike Tamiflu(oseltamivir), which requires two oral doses per day for five days. It is approved by the Ministry of Food and Drug Safety for the treatment of influenza A and B infections in adults and children aged two years and older.Notably, single-dose peramivir therapy demonstrated comparable symptom improvement to Tamiflu in a clinical study involving 1,091 adult patients across 146 medical institutions in Korea, Japan, and Taiwan who received treatment within 48 hours of symptom onset.Building on the success of its IV treatment portfolio, Daehan Nupharm is set to expand its product lineup with the launch of Arginine Premix Injection in March 2025. Arginine, a semi-essential amino acid and pro-drug of nitric oxide (NO), is often supplemented externally due to its limited natural production in the body. It is widely known to support metabolic health, vitality, and sexual function. Unlike conventional vial formulations that dominate the domestic arginine injection market, Daehan Nupharm’s Arginine Premix Injection comes in a ready-to-use IV bag, eliminating the need for compounding, preventing potential contamination during mixing, and enabling safer and more convenient administration.

Daehan Nupharm recorded cumulative sales of KRW 151.2 billion and operating profit of KRW 14.9 billion for the third quarter of 2024.Net profit for the same period reached KRW 12.8 billion. For the third quarter alone, the company posted sales of KRW 48.8 billion and operating profit of KRW 4.0 billion, continuing its strong financial performance. This growth was largely driven by solid sales in its core pharmaceutical business and the successful launch of its new gastroesophageal reflux disease (GERD) treatment,"Rapiduo".Rapiduo is the first and only combination therapy in Korea that pairs rabeprazole with magnesium oxide in a dual-core PPI formulation designed to improve quality of life for GERD patients. The outer layer of magnesium oxide rapidly neutralizes gastric acid and increases pH levels, protecting the inner core of rabeprazole from acid degradation and enabling effective release in the stomach. The product reaches peak plasma concentration within one hour and features reduced tablet size through dual-core technology, enhancing patient convenience. To accelerate market penetration and strengthen product awareness, Daehan Nupharm has been actively organizing medical symposiums. The “Double Protection DUO” symposium series, held three times this month, focuses on Lapiduo’s clinical value. On October 20, a session will feature Professor Ji-Won Kim (Boramae Medical Center) as chair, with lectures by Professor Jung-Won Jeon (Kyung Hee University Hospital at Gangdong) and Dr. Joong-Won Yoon (Samsung Top Internal Medicine Clinic) covering topics such as “Pharmacotherapy for Peptic Ulcers” and “Best Practices for PPI Prescribing in Primary Care.” In addition, the company continues to host its “Obesity & Wellness Injection Symposium” series, launched last year to share medical knowledge in the weight management and wellness field. Starting in Busan, followed by Seoul and Gyeongju, these events serve as key platforms to highlight Daehan Nupharm’s expertise and expand its presence in the market.

Daehan Nupharm recorded KRW 102.4 billion in sales, KRW 10.8 billion in operating profit, and KRW 10.8 billion in net profit for the second quarter of 2024, continuing its solid profitability trend. The strong performance was largely driven by stable growth in the company’s core pharmaceutical business, particularly the successful launch of its gastroesophageal reflux disease (GERD) treatment, Rapiduo Tab. Actively promoted since its release, Rapiduo Tab. combines rabeprazole (PPI) with magnesium oxide, achieving peak plasma concentration within one hour, significantly faster than existing PPI formulations (6~7 hours), thereby overcoming a key limitation of conventional products.In parallel with its commercial success, Daehan Nupharm is expanding its R&D pipeline through specialized research organizations, including the Central Research Institute for human pharmaceuticals, the Biotech Research Institute for biopharmaceuticals, and the Animal Health Research Institute for veterinary medicines.The Central Research Institute plans to add a high-dose 20/350 mg formulation of Rapiduo Tab., while also conducting active research on improved combination drugs for hypertension, hyperlipidemia, and obesity. The Biotech Research Institute is working with domestic biotech companies and overseas research institutes to develop antiviral therapies. Meanwhile, the Animal Health Research Institute has achieved notable milestones, including the 2023 launch of Teramin Tab. (terbinafine) and the world’s first fluconazole formulation for companion dogs, DH Fuzole Tab., launched in June 2024, following earlier development of the human formulation, Fuzole Tab. Beyond R&D investment, Daehan Nupharm is constructing a new GMP production facility to enhance its manufacturing capacity. The new plant will be equipped with state-of-the-art production systems to ensure the large-scale supply of high-quality pharmaceuticals.

Daehan Nupharm has announced the launch of two new veterinary medicines under its exclusive animal hospital brand, DiAange‘DH Fuzole Tab.’, the world’s first fluconazole formulation developed specifically for dogs ‘PROCOX Tab.’, an NSAID (non-steroidal anti-inflammatory drug) containing firocoxib. DH Fuzole Tab. is an antifungal treatment for Malassezia dermatitis, one of the most common dermatological conditions in companion dogs. Skin disorders account for a significant portion of veterinary consultations, and antifungal agents make up a large share of prescribed medications in this field. While human antifungal drugs such as itraconazole, fluconazole, and terbinafine are widely used, there has been a lack of verified animal-specific antifungal formulations, leading veterinarians to rely on human medicines. To address this unmet need, Daehan Nupharm has been actively developing veterinary antifungal products to provide veterinarians with more tailored treatment options. Following the 2023 launch of Teramin Tab. (terbinafine) and several years of development since 2019 based on the human formulation Fuzole Tab., the company has now achieved a global milestone, securing regulatory approval for the world’s first fluconazole formulation for dogs. The newly introduced PROCOX Tab., formulated with firocoxib, offers fast and potent pain relief with high COX-2ivity and minimal COX-1 inhibition. Thisive action reduces the risk of gastrointestinal side effects commonly associated with non-selective NSAIDs. As companion dogs live longer and chronic conditions become more prevalent, the market for veterinary NSAIDs (e.g., meloxicam, carprofen, firocoxib) continues to expand annually. Currently, the domestic market relies heavily on imported products from global pharmaceutical companies. The launch of PROCOX Tab. is expected to enhance treatment accessibility and cost efficiency through local manufacturing while broadening therapeutic options for veterinarians. Daehan Nupharm is committed to transitioning human drugs into veterinary formulations to ensure safer and more effective treatments for animals. The company plans to obtain regulatory approval for three additional veterinary products and file an IND (Investigational New Drug) application for one new compound within this year.

Daehan Nupharm held a groundbreaking and safety prayer ceremony on October 17 for the construction of a new GMP production facility at its Hyangnam plant site, marking a major step toward strengthening its global manufacturing competitiveness. The new facility will involve an investment of KRW 42.9 billion and will cover a total floor area of 15,123 m², consisting of one basement level and five above-ground floors. Construction is scheduled to take 15 months, followed by a validation period, with full-scale production beginning in 2027. This initiative is part of the company’s long-term strategy to build future growth engines. In 2021, Daehan Nupharm opened its Industry-Academia-Research Center to enhance R&D capabilities. Since 2022, the company has strategically advanced the “Hyangnam Project 1·2·3.” Phase 1: Completion of the R&D center in May 2023. Phase 2: Groundbreaking of the new GMP plant, following concept design and detailed engineering. Phase 3: Planned construction of an automated logistics warehouse. The new plant will be equipped with state-of-the-art injection and solid dosage production lines, as well as storage facilities. The injection area will include two vial lines, a lyophilization line, and an ampoule line that incorporate CIP/SIP systems and PUPSIT to ensure aseptic manufacturing. The solid dosage area will feature a BIN system to minimize contamination, with a production capacity of up to 800 million tablets annually. Korea has strengthened its pharmaceutical quality and export competitiveness since joining the Pharmaceutical Inspection Co-operation Scheme (PIC/S) in 2014. In December 2023, the Ministry of Food and Drug Safety (MFDS) revised its GMP regulations to mandate contamination control strategies for sterile products. The construction of Daehan Nupharm’s new plant fully complies with these global regulatory standards, positioning the company to further enhance its export capabilities. As the largest investment in the company’s history, this new facility has been carefully planned from the design stage to optimize operational efficiency. Beyond increasing production capacity, Daehan Nupharm aims to secure a stable supply of high-quality pharmaceuticals, expand global exports, and advance R&D initiatives—paving the way to become a leading global pharmaceutical and biotech company.

Daehan Nupharm recorded KRW 48.3 billion in sales, KRW 4.5 billion in operating profit, and KRW 5.2 billion in net profit for the first quarter of 2024. Following last year’s record-high annual sales of KRW 204.2 billion, the company achieved solid performance driven by strong sales in its core pharmaceutical business. In particular, the newly launched Rapiduo Tab. and well-being injection products have contributed significantly to sales growth. Rapiduo Tab., launched in March, is a treatment for gastroesophageal reflux disease (GERD). It is an improved new drug that combines rabeprazole (PPI) and magnesium oxide, a first-of-its-kind formulation, which reaches maximum plasma concentration within one hour after administration, overcoming the limitation of existing PPI formulations that take 6 to 7 hours to take effect. To expand its growth base, the company is further strengthening R&D efforts across its business divisions, including pharmaceuticals, veterinary medicine, biotechnology, and health functional foods. In addition to Rapiduo Tab., active research is underway on improved combination drugs for hypertension, hyperlipidemia, and obesity. In the veterinary medicine sector, the company is developing various products for both livestock and companion animals. Recently, Daehan Nupharm received regulatory approval for DH Fuzole Tab., a fluconazole-based treatment specifically for Malassezia dermatitis in companion dogs. The company is also pursuing the construction of a new production facility to support future growth. In addition to investing in R&D, Daehan Nupharm plans to ensure a stable supply of high-quality pharmaceuticals through the new plant, establishing a solid foundation to further increase sales in human pharmaceuticals.

Daehan Nupharm recorded KRW 204.2 billion in annual sales for 2023, achieving its highest sales performance to date, along with KRW 18.8 billion in operating profit and KRW 12.5 billion in net profit. The company continues to focus on product research and development across its key business divisions—pharmaceuticals, veterinary medicine, biotechnology, and health functional foods. In addition to the recently launched Rapiduo Tab., R&D efforts are actively underway for improved combination drugs for hypertension, hyperlipidemia, and obesity treatment.In the veterinary medicine division, Daehan Nupharm is expanding its portfolio to cover a wide range of products for both livestock and companion animals. Notably, the company recently received regulatory approval for DH Fuzole Tab., a fluconazole-based treatment for Malassezia dermatitis in dogs. Currently, most antifungal agents prescribed in domestic animal hospitals are human medications. Although fungal skin diseases, including Malassezia infections, are common in companion animals, there has been a lack of approved veterinary drugs, highlighting the need for safe and effective animal-specific antifungal treatments. Daehan Nupharm plans to continuously introduce new products that meet veterinarians’ clinical needs. Through ongoing research and development, the company has successfully developed DH Fuzole Tab. as a veterinary medicine based on its existing human formulation. By pursuing R&D strategies that create synergy across business divisions, Daehan Nupharm aims to launch innovative products and maintain sustainable growth.

Daehan Nupharm’s health functional food brand “DiNU” has launched a new inner beauty product, “DiNU Core Collagen.”Unlike conventional collagen products made from tilapia, pangasius, or other freshwater fish scales and skin, DiNU Core Collagen is manufactured using tuna sourced from clean, open seas through an eco-friendly patented process that eliminates chemical treatments such as acid and alkali processing. The product uses low-molecular-weight collagen produced domestically, setting it apart from existing collagen supplements. A key feature of DiNU Core Collagen is that it is made with Korea’s only tuna-derived collagen, developed in collaboration with a domestic university, and that the entire production process—from raw material to finished product—is carried out in Korea. Building on the successful market entry of “DiNU Paraotics,” a patented double-capsule probiotic product, Daehan Nupharm is leveraging its expertise in obesity and wellness to develop differentiated health functional foods that combine unique raw materials and advanced technology.